department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Tecvayli · pharmadog

pharmadog
drugs
Tecvayli

drug

patient view →

teclistamab

Marketedupdated 2mo ago

by Janssen Biotech Inc

Approved

community read0 votes

all catalysts(11)

approval · 11

TECVAYLI (TECLISTAMAB-CQYV) — FDA approval

TECVAYLI (TECLISTAMAB-CQYV) — FDA approval

TECVAYLI (TECLISTAMAB-CQYV) — FDA approval

TECVAYLI (TECLISTAMAB-CQYV) — FDA approval

TECVAYLI (TECLISTAMAB-CQYV) — FDA approval

TECVAYLI (TECLISTAMAB-CQYV) — FDA approval

TECVAYLI (TECLISTAMAB-CQYV) — FDA approval

TECVAYLI (TECLISTAMAB-CQYV) — FDA approval

TECVAYLI (TECLISTAMAB-CQYV) — FDA approval

TECVAYLI (TECLISTAMAB-CQYV) — FDA approval

TECVAYLI (TECLISTAMAB-CQYV) — FDA approval

view all 11 catalysts →

News(0)

no news has mentioned this drug yet

brand

Tecvayli

generic

teclistamab-cqyv

indication

Refractory Multiple Myeloma

phase

marketed

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Data sources

openFDA · ClinicalTrials.gov

last refreshed 31m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

🐶 often sniffed alongside

top 3

drugTECVAYLI44 co-mentions · 11 sources
tagApproval44 co-mentions · 11 sources
companyJanssen Biotech Inc22 co-mentions · 11 sources

Trials studying teclistamab

phase1A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myelomaactive not recruitingn=140
phase2A Study of Teclistamab in Japanese Participants With Relapsed or Refractory Multiple Myelomacompletedn=40
phase2A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myelomaactive not recruitingn=43
phase2Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)recruitingn=50
phase1A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myelomaactive not recruitingn=74
phase4A Study to Assess Safety of Teclistamab in Indian Participants With Relapsed and Refractory Multiple Myelomarecruitingn=75
phase1Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myelomaactive not recruitingn=302
phase2Outpatient Administration of Teclistamab or Talquetamab for Multiple Myelomarecruitingn=100

more trials →